Michael H. Davidson net worth and biography

Michael Davidson Biography and Net Worth

Dr. Michael Davidson joined NewAmsterdam Pharma as Chief Executive Officer and Executive Board member in August 2020. Before joining NewAmsterdam Pharma, Michael was founder and Chief Medical Officer of Corvidia Therapeutics, which sold to Novo Nordisk in July 2020. Michael is a leading expert in the field of lipidology and has been named in The Best Doctors in America for the past 10 years. Michael was the cofounding Chief Medical Officer of Omthera Pharmaceuticals in 2008, which was later acquired by AstraZeneca Pharmaceuticals in 2013 for $443M. He also founded the Chicago Center for Clinical Research, which became the largest investigator site in the United States and was acquired by Pharmaceutical Product Development in 1996. His research background encompasses pharmaceutical and nutritional clinical trials, including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Michael is board-certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Michael received his BA and MS from Northwestern University and his MD from The Ohio State University College of Medicine.

What is Michael H. Davidson's net worth?: The estimated net worth of Michael H. Davidson is at least $17.83 million as of September 14th, 2026. Davidson owns 792,923 shares of NewAmsterdam Pharma stock worth more than $17,832,838 as of September 20th. This net worth evaluation does not reflect any other investments that Davidson may own. Learn More about Michael H. Davidson's net worth.
How do I contact Michael H. Davidson?: The corporate mailing address for Davidson and other NewAmsterdam Pharma executives is Gooimeer 2-35, Naarden, NH, 1411 DC. NewAmsterdam Pharma can also be reached via phone at 352062971 and via email at [email protected]. Learn More on Michael H. Davidson's contact information.
Has Michael H. Davidson been buying or selling shares of NewAmsterdam Pharma?: Over the course of the past ninety days, Michael H. Davidson has bought $226,500.00 in shares of NewAmsterdam Pharma stock. Most recently, on Monday, September 14th, Michael H. Davidson bought 10,000 shares of NewAmsterdam Pharma stock. The stock was acquired at an average cost of $22.65 per share, with a total value of $226,500.00. Following the completion of the transaction, the chief executive officer now directly owns 792,923 shares of the company's stock, valued at $17,959,705.95. Learn More on Michael H. Davidson's trading history.
Who are NewAmsterdam Pharma's active insiders?: NewAmsterdam Pharma's insider roster includes Juliette Audet (Insider), Michael Davidson (CEO), Johannes Kastelein (Insider), Douglas Kling (COO), Louise Kooij (CAO), Louis Lange (Director), and James Topper (Director). Learn More on NewAmsterdam Pharma's active insiders.
Are insiders buying or selling shares of NewAmsterdam Pharma?: During the last twelve months, NewAmsterdam Pharma insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $226,500.00. During the last twelve months, insiders at the sold shares 24 times. They sold a total of 1,803,533 shares worth more than $58,565,829.23. The most recent insider tranaction occured on September, 14th when CEO Michael H Davidson bought 10,000 shares worth more than $226,500.00. Insiders at NewAmsterdam Pharma own 12.7% of the company. Learn More about insider trades at NewAmsterdam Pharma.
Information on this page was last updated on 9/14/2026.

Michael H. Davidson Insider Trading History at NewAmsterdam Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/14/2026	Buy	10,000	$22.65	$226,500.00	792,923
3/2/2026	Sell	443,707	$33.25	$14,753,257.75	174,144
2/26/2026	Sell	183,332	$33.71	$6,180,121.72	174,144
2/25/2026	Sell	58,253	$35.30	$2,056,330.90	459,859
2/24/2026	Sell	64,708	$36.15	$2,339,194.20	459,859
6/20/2024	Buy	5,000	$17.26	$86,300.00	204,784

Michael H. Davidson Buying and Selling Activity at NewAmsterdam Pharma

NewAmsterdam Pharma Company Overview

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Today's Range

Now: $22.49

$21.29

$22.50

50 Day Range

MA: $27.20

$21.16

$33.29

2 Week Range

Now: $22.49

$21.02

$42.21

Volume

2,076,379 shs

Average Volume

1,371,273 shs

Market Capitalization

$2.69 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.09